Sumandeep Vidyapeeth is private, deemed university located in Piparia, Waghodia, Vadodara, Gujarat, India. It is accredited "A++" grade by NAAC.
Polyetheretherketone (PEEK) has gained attention as an alternative to metallic implants in orthopaedic applications, including arthroplasty, due to its mechanical properties and biocompatibility. This review evaluates the role of PEEK in arthroplasty and other orthopaedic applications by analysing its biomechanical characteristics, surface modifications, and clinical outcomes A comprehensive literature review was conducted using PubMed, PubMed Central (PMC), Scopus, and Embase. Eligible studies included randomised controlled trials, cohort studies, preclinical research, and systematic reviews. PEEK’s elastic modulus (3–4 GPa) closely matches that of human cortical bone, potentially reducing stress shielding and enhancing osseointegration. Its inherent radiolucency improves imaging capabilities, while various surface modification techniques, including hydroxyapatite coatings and nanopatterning, have been developed to enhance bone integration. Despite positive preclinical outcomes, clinical studies are predominantly focused on short- to mid-term results, with limited long-term data on implant survivorship and complications. While PEEK shows promise in orthopaedic applications, further research is necessary to establish its clinical efficacy relative to traditional metals. Addressing the current gaps in long-term studies, regulatory challenges, and manufacturing processes will be crucial for the broader adoption of PEEK implants in orthopaedic surgery. This review highlights the ongoing evolution of PEEK in the field and suggests directions for future research.
Phospholipase C enzymes (plcA, plcB, plcC) represent critical virulence determination in mycobacterium tuberculosis pathogenesis. These enzymes play pivotal roles in disrupting phagosomal maturation, inducing macrophage necrosis, and facilitating immune evasion mechanisms. Protein sequences of phospholipase C gene plcA, plcB,plcC were collected and screened against human to exclude homologous matches and minimize cross-reactivity. Linear B-cell epitopes and T cell epitopes were identified and evaluated for the ability to produce strong antigenicity, solubility, toxicity and allergenicity. Suitable segments were linked using EAAK for adjuvant fusion, GPGPG between T-cell epitopes, and AAY between cytotoxin T-cell epitopes, with the L7/L12 ribosomal proteins at N-terminus as immunostimulatory adjuvant, The full vaccine structures were modelled in 3-D and improved for accuracy, and interaction of tuberculosis related proteins were analysed. Immunological potent epitopes for all 3 phospholipase C enzymes with favourable physiochemical properties and structural stability were identified. Immune simulation predicted effective stimulation of both humoral and cell-mediated responses. Molecular docking revealed promising interactions with key targets, characterized by favourable binding energies and stable complex formation dominated by hydrogen bonds and electrostatic interactions, suggesting potential functional efficacy of the designed vaccine. The study presents a strong potential of rationally designed multi-epitope vaccine candidate targeting phospholipase C virulence factor of M. tuberculosis. The computational workflow established a rigorous selection process for immunologically relevant epitopes assembled into chimeric construct with predicted vaccine potential. Further experimental validation through invitro antigenicity assay and in-vivo immunization studies is needed to assess the translational potential of this computationally designed vaccine.
Background Preoperative anxiety significantly impacts perioperative outcomes through neuroendocrine activation, increased anaesthetic requirements, and impaired recovery. The Amsterdam Preoperative Anxiety and Information Scale (APAIS) provides a validated, rapid tool for identifying high-risk patients. This study aimed to determine preoperative anxiety prevalence and identify associated demographic and clinical predictors among adult patients scheduled for elective surgery using the APAIS. Methods This cross-sectional study was conducted at a tertiary care hospital in Western India (July 2023–June 2024). One hundred adults scheduled for elective surgery were recruited through systematic random sampling. The six-item APAIS was administered, with clinically significant anxiety defined as anxiety subscale score > 11. Analysis included descriptive statistics, t-tests, ANOVA, chi-square tests, correlations, and multiple regression using R version 4.5.2. Results Clinically significant anxiety prevalence was 48% (95% CI: 38.1–57.9%). Mean APAIS scores were: anxiety 11.63 ± 3.23, information 5.29 ± 1.57, total 16.93 ± 4.36. The APAIS showed good internal consistency (Cronbach α = 0.806). Significant predictors included unmarried status (Cohen d = 1.33, p < 0.001), younger age ( r = − 0.43, p < 0.001), oncological procedures (η²=0.30, p < 0.001), and higher education (η²=0.11, p = 0.031). Surgery-related anxiety exceeded anaesthesia-related anxiety (6.42 ± 1.88 vs 5.21 ± 1.81; p < 0.001; d = 0.68). Only marital status remained independently significant in multivariate analysis (B = 2.90, p = 0.002; OR = 3.90). Conclusion Nearly half of elective surgery patients experience clinically significant anxiety, with unmarried status as the strongest predictor. Routine APAIS screening can identify high-risk patients for targeted interventions.
Rheumatoid Arthritis (RA) is a chronic autoimmune disease that primarily affects the synovial tissue, leading to joint destruction, disability, and socioeconomic burden. Despite advancements in treatment options, including biologic and targeted synthetic Disease-Modifying Antirheumatic Drugs (DMARDs), a proportion of patients still do not respond adequately to existing therapies. Upadacitinib, a novel selective JAK1 inhibitor, has recently been approved for the treatment of moderately to severely active RA in patients with an inadequate response or intolerance to methotrexate. This review summarizes the chemistry, pharmacokinetics, pharmacodynamics, clinical trials, safety, and efficacy of upadacitinib in the treatment of RA. Upadacitinib demonstrates dose-proportional pharmacokinetics with rapid absorption and elimination, and its exposure is not significantly affected by mild to severe renal or hepatic impairment. Pharmacodynamic studies show that upadacitinib selectively and reversibly inhibits JAK1, leading to the suppression of proinflammatory cytokine signaling. Clinical trials have demonstrated the efficacy of upadacitinib in achieving treatment targets, such as low disease activity and clinical remission, in patients with an inadequate response to conventional synthetic DMARDs or biologic DMARDs. Upadacitinib has also shown superiority over adalimumab and methotrexate in clinical and functional outcomes. The safety profile of upadacitinib is generally consistent across various patient populations, with the most common adverse events being nasopharyngitis, upper respiratory tract infections, and elevated blood creatine phosphokinase levels. However, upadacitinib is a promising treatment option for patients with RA, offering an effective and well-tolerated alternative for those who have not responded adequately to existing therapies.
Aflatoxins are highly toxic secondary metabolites produced by Aspergillus species. These toxins pose significant safety concerns in herbal products due to carcinogenic hepatotoxic immunosuppressive and mutagenic effects. Their presences in herbal products poses a significant safety concern. This review specifically addresses method development, validation stategies, comparative analytical performance, and emerging detection technologies for aflotoxin determaintion in herbal matrices, while alos integrating recent advances in biosensor based detection, green sample prepartion approaches, and regulatory validation framworks relevant to hearbal products. Sample preparation techniques such as QuEChERS, solid-phase extraction (SPE) and immunoaffinity column (IAC) remain established methods for extracting these toxins from complex herbal and food matrices with recovery rates of 80–110